This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of teriflunomide
MSMED_TERIFLUNOMIDE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
405 |
4. Check minimum number of events
Min. number of events
3
|
405 |
5. Include endpointsNone |
405 |
6. Filter based on genotype QC (FinnGen only) |
386 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of teriflunomide
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- L04AA Selective immunosuppressants
- Other degenerative diseases of the nervous system
- ILD medications: immunosuppressive drugs
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 386 | 288 | 98 |
| Unadjusted period prevalence (%) | 0.09 | 0.10 | 0.04 |
| Median age at first event (years) | 44.83 | 45.31 | 43.40 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 405
- Matched controls
- 4050
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
154.9
319.6
160
17
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
36.7
314.6
267
203
L03AB07
ATC
interferon beta-1a; parenteral
254.8
307.7
190
14
L04AA31
ATC
[U] teriflunomide
+∞
307.7
405
*
109
Kela drug reimbursment
Multiple sclerosis
15305.1
307.7
400
20
G35
ICD-10 Finland
Multiple sclerosis
+∞
307.7
405
32
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
307.7
405
20
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
5358.3
307.7
391
21
H46
ICD-10 Finland
Optic neuritis
92.6
254.6
136
22
TAB00
NOMESCO Finland
Lumbar puncture
30.7
230.4
174
97
L04AK02
ATC
teriflunomide; oral
+∞
197.6
173
*
L04AX07
ATC
dimethyl fumarate; oral
125.5
188.8
96
10
N04BB01
ATC
amantadine; oral
76.2
172.3
94
16
C10AC01
ATC
colestyramine; oral
33.4
167.0
114
47
L03AX13
ATC
glatiramer acetate; parenteral
257.5
140.7
137
8
N86
ICPC
Multiple sclerosis
209.3
130.2
129
9
G04BD12
ATC
mirabegron; oral
12.6
99.7
112
119
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
33.1
93.9
62
22
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
9.4
90.1
133
201
L03AB08
ATC
interferon beta-1b; parenteral
280.0
89.4
88
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
23.7
88.0
66
33
XA800
NOMESCO Finland
Neuropsychological investigation
11.3
84.4
101
116
M03BX01
ATC
baclofen; systemic
20.5
79.1
63
36
N07XX09
ATC
[U] dimethyl fumarate
189.4
76.0
77
5
G04BD09
ATC
trospium; oral
36.2
75.2
48
15
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
21.7
74.9
58
31
164
Kela drug reimbursment
Fingolimod
118.5
72.8
77
8
XKD00
NOMESCO Finland
Uroflowmetry
11.4
72.8
84
91
XCK00
NOMESCO Finland
Perimetry
12.9
70.8
74
69
XKD06
NOMESCO Finland
Physiologic investigation of micturition
20.9
67.6
53
29
353
Kela drug reimbursment
Cladribine and fingolimod
116.4
64.1
68
7
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
8.8
57.7
81
112
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
10.3
56.9
69
79
R20.2
ICD-10 Finland
Paraesthesia of skin
6.6
52.8
101
195
G04BD08
ATC
solifenacin; oral
10.5
44.6
52
56
L04AA27
ATC
[U] fingolimod
90.6
43.9
48
6
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.6
41.1
129
377
ZX120
NOMESCO Finland
Intravenous
5.9
38.4
79
161
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
9.7
38.3
47
54
L03AB13
ATC
peginterferon beta-1a; parenteral
402.5
37.7
37
*
H02AB04
ATC
methylprednisolone; systemic
4.5
35.0
106
298
2AB04, ,
NOMESCO Finland
83.8
34.5
38
5
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
10.4
33.8
39
41
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
98.6
33.3
36
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
5.7
31.2
64
129
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
11.2
31.1
34
33
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.9
29.2
73
175
XKC03
NOMESCO Finland
Water cystometry
10.5
28.9
33
34
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
5.7
28.0
56
110
UKC02
NOMESCO Finland
Cystoscopy
4.7
26.4
69
171
L04AG12
ATC
ofatumumab; parenteral
+∞
26.3
25
*
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
10.4
26.2
30
31
G04BD07
ATC
tolterodine; oral
9.1
26.1
33
39
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
24.2
23
*
R1250
NOMESCO Finland
Evaluation of functional capability
8.0
24.1
34
46
R35
ICD-10 Finland
Polyuria
5.8
23.8
46
87
N06BA07
ATC
modafinil; oral
30.4
23.5
31
11
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
38.9
23.3
29
8
L04AA40
ATC
cladribine; oral
127.2
22.8
24
*
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
19.8
22.1
33
18
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
232.0
21.8
22
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.5
21.4
56
138
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
39.5
21.0
26
7
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
81.2
20.9
23
*
Z2445
NOMESCO Finland
Psychologist
4.8
20.8
51
119
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
220.9
20.8
21
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
5.0
19.9
45
98
N03AX12
ATC
[U] gabapentin; oral
3.2
19.8
98
372
H53.2
ICD-10 Finland
Diplopia
7.0
18.5
29
44
TKC22
NOMESCO Finland
Catheterisation instruction
23.0
18.4
26
12
N06AX16
ATC
venlafaxine; oral
2.8
17.4
108
462
SPAT1229
SPAT
Assessment of need for aid
5.4
16.3
33
65
R33
ICD-10 Finland
Retention of urine
6.4
15.8
27
45
N03AE01
ATC
clonazepam; systemic
4.5
15.7
40
96
Z3226
NOMESCO Finland
Physiotherapist
2.7
15.3
97
418
R4110
NOMESCO Finland
Physiotherapy
2.5
15.0
131
657
G04BD04
ATC
oxybutynin; oral, transdermal
5.0
14.5
32
68
H53.1
ICD-10 Finland
Subjective visual disturbances
3.7
14.3
49
146
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.4
14.3
29
57
N02BF01
ATC
gabapentin; oral
3.5
14.1
52
163
N03AX16
ATC
[U] pregabalin
2.5
13.7
112
542
L28
ICPC
Limited function/disability (L)
3.1
13.6
61
216
XCD10
NOMESCO Finland
Electrophysiological examination of eye
10.2
13.4
26
27
R4150
NOMESCO Finland
Neuropsychological rehabilitation
9.8
12.7
25
27
R5110, ,
SPAT
4.5
11.9
30
71
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
66.9
11.7
13
*
A02BC02
ATC
pantoprazole; systemic
2.1
11.5
273
1988
TKC20
NOMESCO Finland
Catheterisation of bladder
4.4
11.5
29
69
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.9
11.2
56
210
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
12.4
10.9
19
16
Z3231
NOMESCO Finland
Registered nurse
2.2
10.7
123
680
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.5
10.7
39
121
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.4
10.3
26
62
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
41.2
10.0
12
*
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.6
9.9
61
256
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
26.8
9.9
13
5
4AA23, ,
NOMESCO Finland
56.4
9.7
11
*
R4120
NOMESCO Finland
Occupational therapy
3.1
9.5
41
141
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
102.3
9.5
10
*
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
102.3
9.5
10
*
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
+∞
9.4
9
*
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.1
9.3
100
536
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
8.0
9.2
20
26
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
4.8
9.2
21
46
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
4.0
9.1
26
68
R42
ICD-10 Finland
Dizziness and giddiness
2.3
8.9
80
398
XKD03
NOMESCO Finland
Urethral pressure profilometry
8.9
8.9
18
21
M03BX02
ATC
tizanidine; oral
2.0
8.9
292
2282
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.4
8.8
63
284
CS494
NOMESCO Finland
Other visual field testing
9.3
8.6
17
19
G04BD11
ATC
fesoterodine; oral
10.4
8.6
16
16
J01EA01
ATC
trimethoprim; systemic
2.0
8.5
118
693
N04BD01
ATC
selegiline; oral
17.6
8.1
12
7
R90.8
ICD-10 Finland
Other abnormal findings on diagnostic imaging of central nervous system
9.2
8.1
16
18
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
4.2
7.9
21
52
G37.8
ICD-10 Finland
Other specified demyelinating diseases of central nervous system
81.5
7.4
8
*
AA1AG
NOMESCO Finland
Short MRI examination of brain with median intensity magnet
6.8
7.2
17
26
SPAT1216
SPAT
Assessment of functional ability
2.5
7.2
45
190
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.9
6.9
32
115
R39.1
ICD-10 Finland
Other difficulties with micturition
6.9
6.9
16
24
L04AE01
ATC
fingolimod; oral
40.8
6.8
8
*
A28
ICPC
Limited function/disability NOS
2.7
6.7
36
140
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
23.0
6.7
9
*
G04CA02
ATC
tamsulosin; oral
2.7
6.7
36
141
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
12.5
6.6
11
9
N02BF02
ATC
pregabalin; oral
2.8
6.4
33
126
L01BB04
ATC
cladribine; systemic
+∞
6.3
6
*
L04AX09
ATC
diroximel fumarate; oral
+∞
6.3
6
*
U13
ICPC
Bladder symptom/complaint other
5.7
6.1
16
29
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
130
61
30.91
182.29
1.2
1.1
—
—
—
0
0
90
23
50.02
151.27
1.0
1.1
—
—
—
0
0
91
30
38.83
142.58
1.0
1.1
211.48
228.00
mg/l
0.28
76
24
91
31
37.57
141.13
1.1
1.1
54.06
31.19
mg/l
4.15
72
25
398
1709
77.77
126.03
13.4
5.9
1.64
1.94
e9/l
8.01
385
1552
398
1719
76.99
125.14
13.5
6.5
0.20
0.18
e9/l
3.45
384
1556
171
250
11.11
121.98
3.0
2.6
9.63
10.45
g/l
2.35
156
234
396
1904
49.51
106.08
13.5
8.9
3.23
3.96
e9/l
20.51
381
1673
113
114
13.36
104.36
2.1
1.6
0.03
0.02
iu/ml
—
6
15
74
36
24.93
100.18
1.0
1.1
—
—
—
0
0
75
38
24.00
99.84
1.0
1.1
—
—
—
0
0
72
38
22.83
94.04
1.0
1.1
—
—
—
0
0
62
23
31.65
92.53
1.0
1.1
0.97
1.17
u/l
—
19
10
56
19
34.04
85.84
1.2
1.1
1624.70
1851.37
miu/ml
0.41
56
19
87
79
13.75
85.23
1.1
1.3
147.45
9.69
e6/l
0.50
73
61
87
79
13.75
85.23
1.1
1.4
61.99
192.78
e6/l
0.62
74
64
79
80
12.03
71.65
1.0
1.3
3.47
3.55
mmol/l
0.36
73
75
63
47
15.69
68.85
1.3
1.1
—
—
—
0
0
108
200
7.00
59.23
3.2
1.6
0.91
1.32
g/l
2.09
108
189
42
29
16.04
47.45
2.9
2.1
882.50
817.76
e6/l
0.24
42
29
50
5
113.77
46.96
1.2
1.0
—
—
—
0
0
189
683
4.31
45.95
3.7
2.4
0.11
0.26
e6/l
1.42
164
499
223
909
4.23
45.76
4.5
2.7
—
—
—
0
0
272
1286
4.40
44.99
2.5
2.3
97.88
73.37
nmol/l
18.91
266
1219
35
20
19.06
43.34
2.6
2.6
—
—
—
0
0
104
271
4.82
38.07
2.5
2.2
36.43
18.33
au/ml
—
6
24
318
1927
4.03
31.52
6.9
3.5
—
580.23
—
0
26
111
386
3.58
26.52
3.6
2.2
0.92
0.97
e6/l
0.08
68
198
42
72
6.39
24.05
4.1
3.9
3.07
4.43
e9/l
3.97
42
72
42
72
6.39
24.05
4.1
4.3
55.21
57.88
%
0.62
42
72
29
11
28.26
21.65
2.8
2.2
—
—
—
0
0
100
377
3.19
20.52
3.6
2.3
6.45
3.15
e6/l
1.48
57
190
236
1488
2.40
16.46
3.3
5.4
9.14
10.28
umol/l
2.04
231
1419
240
1551
2.34
15.44
5.4
2.8
0.00
0.00
estimate
-0.00
63
316
239
1550
2.32
15.14
7.6
3.9
0.00
0.00
estimate
0.50
62
307
240
1566
2.31
14.89
5.4
2.8
0.00
0.02
estimate
0.80
62
294
181
1106
2.15
12.55
3.5
4.2
38.99
37.42
g/l
5.89
173
1045
64
245
2.91
12.42
2.7
2.2
61.01
2509.61
u/l
1.94
18
106
235
1604
2.11
11.99
2.4
3.8
5.83
6.35
mmol/l
7.82
222
1476
23
25
9.68
11.65
2.7
3.2
50.31
46.10
%
—
16
10
138
796
2.11
10.78
2.2
1.4
1.84
2.17
g/l
3.20
113
543
42
144
3.14
9.83
1.3
2.3
68.78
68.43
g/l
0.17
42
136
389
3414
4.53
9.54
10.0
9.9
16.90
19.14
mg/l
0.73
289
2573
359
3052
2.55
8.59
18.8
12.0
13.75
14.00
%
0.53
359
3002
12
6
20.55
8.51
2.7
1.8
—
—
—
0
0
366
3168
2.61
7.90
9.2
8.1
97.16
93.25
ml/min/173m2
4.26
320
2590
39
146
2.85
7.83
1.3
1.4
—
—
—
0
0
176
1226
1.77
7.16
6.1
2.7
—
—
—
0
0
13
14
9.55
6.83
1.3
1.7
—
—
—
0
0
405
3887
+∞
6.67
24.3
14.8
41.52
40.85
%
4.20
391
3744
44
192
2.45
6.54
2.5
1.6
—
—
—
0
0
288
2348
1.78
6.41
4.6
6.7
73.77
73.38
u/l
0.06
271
2226
370
3283
2.47
6.41
8.9
9.5
3.89
3.92
mmol/l
1.78
363
3194
405
3894
+∞
6.29
24.5
14.9
137.55
137.32
g/l
0.17
405
3863
20
71
2.91
4.45
1.1
2.0
—
—
—
0
0
282
2395
1.58
4.31
2.8
3.7
8.15
8.48
mm/h
0.24
261
2276
155
1158
1.55
4.23
3.0
3.1
28.31
30.87
u/l
0.56
150
1113
111
783
1.58
3.85
6.8
3.0
0.00
0.01
estimate
0.80
63
306
132
977
1.52
3.66
4.8
7.6
1.06
1.07
inr
0.07
45
327
307
3369
0.63
3.60
3.1
3.5
1.51
1.48
mmol/l
0.63
289
3239
12
31
3.96
3.52
1.4
1.6
—
—
—
0
0
6
7
8.68
3.27
1.2
1.3
—
—
—
0
0
6
7
8.68
3.27
1.2
1.1
—
—
—
0
0
343
3125
1.64
3.20
4.8
4.6
1.58
2.09
mu/l
0.77
330
3003
313
3400
0.65
3.11
3.4
3.7
3.02
2.96
mmol/l
0.68
297
3260
6
8
7.59
3.06
1.2
1.4
—
—
—
0
0
296
3248
0.67
3.04
2.9
3.2
1.24
1.28
mmol/l
0.48
278
3110
6
189
0.31
2.89
1.2
1.4
—
—
—
0
0
6
189
0.31
2.89
1.2
1.4
—
—
—
0
0
6
189
0.31
2.89
1.2
1.4
—
—
—
0
0
6
189
0.31
2.89
1.2
1.4
—
—
—
0
0
14
319
0.42
2.75
1.6
1.5
—
—
—
0
0
7
198
0.34
2.60
1.3
1.5
—
—
—
0
0
5
7
7.21
2.55
1.2
1.6
—
—
—
0
0
7
16
4.43
2.48
1.0
1.0
—
—
—
0
0
314
3377
0.69
2.44
3.2
3.5
4.92
4.86
mmol/l
0.53
299
3253
5
8
6.31
2.38
1.2
1.1
—
—
—
0
0
33
197
1.74
2.20
1.2
1.4
185.63
263.42
miu/ml
—
8
106
9
30
3.04
2.16
1.1
1.3
—
—
—
0
0
7
19
3.73
2.16
1.0
1.2
—
—
—
0
0
18
88
2.09
2.14
2.1
2.2
—
—
—
0
0
17
83
2.09
2.04
2.1
1.9
—
—
—
0
0
275
2986
0.75
1.86
3.5
3.8
—
—
—
0
0
295
2709
1.33
1.76
4.1
4.1
14.23
14.29
pmol/l
0.21
284
2580
0
46
0.00
1.71
0.0
1.6
—
—
—
0
0
0
46
0.00
1.71
0.0
1.6
—
—
—
0
0
117
955
1.32
1.69
1.7
1.7
102.25
98.37
pmol/l
0.39
64
528
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
19
3.19
1.66
1.0
1.3
—
—
—
0
0
19
106
1.83
1.61
1.3
1.6
—
—
—
0
0
49
350
1.46
1.59
1.5
1.8
—
—
—
0
0
268
2898
0.78
1.58
3.4
4.1
35.55
37.83
mmol/mol
6.35
257
2791
0
43
0.00
1.53
0.0
2.2
—
5.86
—
0
43
145
1234
1.27
1.51
5.1
5.8
1.23
1.22
mmol/l
2.08
121
1060
11
214
0.50
1.48
3.6
7.3
1.02
0.99
mmol/l
—
6
164
11
207
0.52
1.35
1.9
1.8
—
—
—
0
0
84
677
1.30
1.32
5.8
3.0
1.01
1.02
kg/l
—
10
74
5
117
0.42
1.27
2.8
7.4
22.44
24.64
mmol/l
—
5
109
12
214
0.55
1.25
3.4
7.3
12.34
13.78
kpa
1.04
12
204
12
214
0.55
1.25
3.4
7.3
4.97
5.15
kpa
0.34
12
203
103
863
1.26
1.20
1.6
1.5
—
—
—
0
0
11
198
0.54
1.19
1.3
1.9
1.97
2.99
mg/l
—
6
144
40
531
0.73
1.12
1.6
1.6
—
—
—
0
0
126
1090
1.23
1.10
3.9
5.0
1.23
1.22
mmol/l
1.45
116
1010
5
21
2.40
1.09
1.0
1.8
2.02
3.35
mg/l
—
5
21
47
360
1.35
1.07
1.9
2.0
5.94
6.93
umol/l
0.23
39
310
10
177
0.55
1.04
3.8
8.1
133.50
125.67
g/l
—
10
170
14
223
0.61
0.99
1.6
2.3
14.20
13.61
nmol/l
0.08
14
213
19
124
1.56
0.98
1.2
2.5
—
—
—
0
0
5
23
2.19
0.98
1.0
1.2
—
—
—
0
0
0
29
0.00
0.98
0.0
1.5
—
—
—
0
0
0
29
0.00
0.98
0.0
1.5
—
—
—
0
0
34
449
0.73
0.94
1.4
1.9
—
—
—
0
0
36
271
1.36
0.93
3.5
3.2
28.57
30.91
%
0.73
30
211
16
102
1.59
0.92
1.1
1.1
4.10
2.80
u/ml
—
8
51
5
104
0.47
0.90
1.6
1.5
—
—
—
0
0
105
911
1.21
0.88
2.6
2.5
87.23
17.41
ng/l
0.46
59
399
12
191
0.62
0.86
2.8
4.0
1.90
5.64
ug/l
1.63
12
142
56
455
1.27
0.86
2.1
3.0
565.00
391.81
ng/l
0.14
25
249
15
96
1.58
0.85
1.9
2.1
0.59
0.67
%
0.50
15
96
31
233
1.36
0.82
1.8
2.6
—
—
—
0
0
129
1437
0.85
0.80
2.2
2.3
—
—
—
0
0
0
24
0.00
0.79
0.0
1.0
—
—
—
0
0
8
48
1.68
0.79
1.0
1.1
—
—
—
0
0
8
48
1.68
0.79
1.0
1.1
—
—
—
0
0
24
174
1.40
0.78
3.0
3.1
1.24
1.23
mmol/l
0.59
19
148
0
26
0.00
0.78
0.0
1.4
—
—
—
0
0
0
26
0.00
0.78
0.0
1.5
—
—
—
0
0
6
34
1.78
0.76
1.0
1.1
—
—
—
0
0
6
34
1.78
0.76
1.0
1.1
—
—
—
0
0
6
34
1.78
0.76
1.0
1.1
—
—
—
0
0
5
26
1.93
0.71
1.4
1.4
1.52
1.57
g/l
—
5
26
7
43
1.64
0.67
1.0
1.1
—
—
—
0
0
18
128
1.43
0.67
1.3
1.7
0.25
0.24
g/l
0.37
18
123
5
28
1.80
0.66
1.4
1.5
0.64
1.02
g/l
—
5
28
0
20
0.00
0.60
0.0
1.5
—
—
—
0
0
0
21
0.00
0.60
0.0
10.3
—
39.40
—
0
10
0
22
0.00
0.59
0.0
1.7
—
—
—
0
0
0
22
0.00
0.59
0.0
1.7
—
—
—
0
0
0
22
0.00
0.59
0.0
1.7
—
—
—
0
0
18
132
1.38
0.58
1.3
1.6
1.11
1.20
g/l
0.74
18
125
28
351
0.78
0.58
1.3
1.9
—
—
—
0
0
102
916
1.15
0.57
1.9
2.4
48.49
57.45
u/l
2.49
95
861
30
239
1.28
0.57
1.2
1.6
—
—
—
0
0
28
221
1.29
0.57
1.9
4.2
207.14
235.24
u/l
1.12
28
214
5
87
0.57
0.57
2.4
1.9
13.20
13.17
%
—
5
87
85
754
1.16
0.56
1.5
1.7
0.42
0.69
mg/l
4.77
58
556
10
147
0.67
0.54
1.7
1.5
—
—
—
0
0
18
237
0.75
0.53
1.7
1.4
—
—
—
0
0
6
39
1.55
0.53
1.5
1.4
—
—
—
0
0
6
39
1.55
0.53
1.5
1.4
—
—
—
0
0
6
39
1.55
0.53
1.5
1.4
—
—
—
0
0
9
63
1.44
0.52
1.3
1.4
—
—
—
0
0
17
225
0.74
0.52
1.6
2.1
15.21
38.15
u/ml
1.39
17
214
6
40
1.51
0.52
1.5
1.4
—
—
—
0
0
17
127
1.35
0.50
1.1
1.1
—
—
—
0
0
7
45
1.57
0.49
1.3
1.3
—
—
—
0
0
24
191
1.27
0.47
1.7
1.5
—
—
—
0
0
10
68
1.48
0.47
1.9
1.5
—
—
—
0
0
76
679
1.15
0.47
1.3
1.3
14.00
25.42
iu/ml
1.08
15
233
21
165
1.29
0.46
1.2
1.7
—
—
—
0
0
99
904
1.13
0.44
2.1
3.0
2.34
2.35
mmol/l
0.21
89
836
7
51
1.38
0.44
1.9
3.4
—
5348.00
—
0
5
9
127
0.70
0.44
1.6
1.7
—
—
—
0
0
18
228
0.78
0.42
1.4
1.5
—
—
—
0
0
5
32
1.57
0.42
1.0
1.5
69.00
70.03
umol/l
—
5
32
305
3133
0.89
0.42
3.2
3.4
5.53
5.68
mmol/l
1.89
283
2965
30
250
1.22
0.41
2.7
6.5
106.23
104.54
mmol/l
1.80
30
250
5
33
1.52
0.41
1.0
1.2
—
—
—
0
0
5
33
1.52
0.41
1.0
1.2
—
—
—
0
0
0
15
0.00
0.41
0.0
2.4
—
—
—
0
0
0
17
0.00
0.40
0.0
1.8
—
—
—
0
0
0
17
0.00
0.40
0.0
3.4
—
596.88
—
0
17
0
17
0.00
0.40
0.0
1.8
—
—
—
0
0
29
242
1.21
0.40
1.2
1.7
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
23.95
—
0
19
0
19
0.00
0.39
0.0
2.0
—
—
—
0
0
42
365
1.17
0.38
1.4
1.3
34.96
27.54
iu/l
0.56
36
317
9
67
1.35
0.38
1.9
3.4
—
845.71
—
0
7
17
134
1.28
0.37
1.4
1.7
—
—
—
0
0
6
41
1.47
0.36
1.5
1.4
—
—
—
0
0
6
41
1.47
0.36
1.5
1.4
—
—
—
0
0
6
41
1.47
0.36
1.0
2.2
—
—
—
0
0
82
751
1.12
0.36
1.6
2.1
—
—
—
0
0
6
87
0.69
0.33
1.2
1.2
4.18
2.88
ug/l
—
6
79
24
284
0.84
0.33
3.6
5.2
—
—
—
0
0
72
785
0.90
0.32
1.4
1.6
1.58
1.45
mmol/l
0.49
65
698
8
106
0.75
0.29
2.8
1.5
—
—
—
0
0
36
319
1.14
0.27
2.0
2.7
19.74
23.31
%
0.51
14
89
73
677
1.10
0.26
1.6
2.0
—
—
—
0
0
11
87
1.27
0.24
1.2
2.5
7.35
10.35
mg/l
0.92
11
81
10
78
1.29
0.24
1.1
1.3
—
1.28
—
0
6
0
11
0.00
0.21
0.0
2.5
—
34.02
—
0
11
0
11
0.00
0.21
0.0
1.6
—
196.36
—
0
11
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
7.71
—
0
10
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
2.0
—
—
—
0
0
0
12
0.00
0.21
0.0
3.0
—
131.25
—
0
12
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
16
187
0.85
0.20
3.5
5.8
0.98
1.32
mmol/l
1.29
16
181
6
52
1.16
0.19
2.7
2.8
24.25
23.84
mmol/l
—
6
52
14
120
1.17
0.16
4.1
5.7
25.66
24.59
mmol/l
0.91
14
120
165
1686
0.96
0.11
2.5
2.8
96.91
88.60
ug/l
0.36
156
1614
26
240
1.09
0.11
1.8
1.9
0.57
0.63
ug/l
0.24
19
103
10
86
1.17
0.11
1.5
1.0
1.14
1.47
u/ml
—
5
45
58
605
0.95
0.10
3.7
3.8
8.20
10.72
mg/mmol
0.22
33
387
12
106
1.14
0.10
1.1
1.3
—
3.33
—
0
11
94
966
0.96
0.09
1.7
1.6
—
—
—
0
0
6
56
1.07
0.08
1.0
1.2
—
—
—
0
0
6
70
0.86
0.07
1.3
1.2
—
—
—
0
0
8
76
1.05
0.07
1.0
1.2
—
—
—
0
0
8
77
1.04
0.07
1.8
1.7
—
—
—
0
0
65
669
0.97
0.06
1.2
1.3
2.33
10.95
u/ml
2.16
26
307
64
655
0.97
0.04
2.0
2.0
2.63
2.77
mg/l
0.28
56
570
10
108
0.92
0.03
1.2
1.2
—
—
—
0
0
21
219
0.96
0.03
1.8
2.1
80.25
79.44
ml/min/173m2
0.03
12
85
24
231
1.04
0.03
1.2
1.0
—
—
—
0
0
37
361
1.03
0.02
1.3
1.2
202.09
158.19
iu/ml
0.27
15
157
68
671
1.02
0.02
2.0
1.9
—
—
—
0
0
10
107
0.93
0.02
1.2
1.2
—
—
—
0
0
14
133
1.05
0.01
1.6
1.4
—
—
—
0
0
90
907
0.99
0.01
1.3
1.3
0.49
1.88
u/ml
1.61
19
266
12
124
0.97
0.00
1.1
1.2
—
—
—
0
0
42
416
1.01
0.00
2.0
3.0
471.06
630.46
ng/l
0.25
30
343
5
55
0.91
0.00
1.0
2.2
49.00
214.60
ug/l
—
5
48
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
1.20
—
0
7
40
400
1.00
-0.00
2.0
2.8
0.86
0.83
mmol/l
0.83
40
383
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.9
—
—
—
0
0
8
79
1.01
-0.00
1.0
1.1
—
14.74
—
0
7
0
8
0.00
-0.00
0.0
1.0
—
104.25
—
0
8
0
9
0.00
-0.00
0.0
2.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
3.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
4.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
9
90
1.00
-0.00
1.6
1.2
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
8
81
0.99
-0.00
1.9
1.9
208.00
232.57
pmol/l
—
8
76
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_TERIFLUNOMIDE – Use of teriflunomide
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).